FDA approved Valeant’s brodalumab with a boxed warning for suicidal ideation.
On Feb. 15, 2017, FDA approved Valeant’s Siliq (brodalumab) for the treatment of moderate-to-severe plaque psoriasis. The monoclonal antibody (mAb) works by binding to the IL-17 receptor and is meant for patients who are candidates for systemic therapy or phototherapy, and have failed to respond or stopped responding to other systemic therapies.
Brodalumab does have some notable adverse events, FDA said in a statement. During clinical trials, there were instances of patients demonstrating suicidal ideation. FDA noted, however, that a casual association between brodalumab and an increased risk of suicidal behavior or ideation has not been established. Because of this risk, the drug will come with a boxed warning and will only be available under a Risk Evaluation and Mitigation Strategy (REMS) program.
In 2015, Amgen dropped out of co-developing the mAb with AstraZeneca when it became clear patients were demonstrating thoughts of suicide. In September 2015, Valeant took over the commercialization and development of the mAb.
Source: FDA
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
AES Clean Technology Launches Next-Generation OSM Utility Solution for Cleanrooms at INTERPHEX 2025
April 2nd 2025Officially launched at INTERPHEX 2025, the Omni ASCENT is a next-generation off-site manufactured vertical utility solution that offers optimized cleanroom flexibility and efficiency.